Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BMLBMLKF 69 Days Sales Outstanding is 71.72 as of Mar. 2026, which is 9% above its 10-year median of 65.60. GuruFocus rates BMLKF with a GF Score™ of 69/100 and a GF Value™ of $26.57. The stock has 2 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, BML ranks worse than 50.75% on this metric.
BML's average Accounts Receivable for the
three
months ended in Mar. 2026 was $177.3 Mil. BML's Revenue for the
three
months ended in Mar. 2026 was $225.5 Mil.
Hence, BML's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 71.72.
The historical rank and industry rank for BML's Days Sales Outstanding or its related term are showing as below:
BMLKF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.65 Med: 65.6 Max: 72.32
Current: 67.73
During the past 13 years, BML's highest Days Sales Outstanding was 72.32. The lowest was 64.65. And the median was 65.60.
BMLKF's Days Sales Outstanding is ranked worse than 50.75% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs BMLKF: 67.73
BML's Days Sales Outstanding
increased
from Mar. 2025 (70.17) to Mar. 2026 (71.72).
BML (OTCPK:BMLKF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
BML Days Sales Outstanding Related Terms
BML Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for BML's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMLKF vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, BML's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where BML's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BML (BMLKF) has a Days Sales Outstanding of 71.72 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BML and its competitors. This is near median its historical median of 65.60. Over the past decade, BML's Days Sales Outstanding has ranged from 64.65 to 72.32. According to the industry distribution chart, BML ranks #102 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 50.7%.
Is BML's Days Sales Outstanding too high?
BML's current Days Sales Outstanding of 71.72 is near median its 10-year median of 65.60. Over the past 10 years, this metric has ranged from a low of 64.65 to a high of 72.32. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. BML's value of 71.72 is 6.1% above this industry median. Based on the distribution chart, BML ranks #102 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, BML has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does BML's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #102 out of 201 companies for Days Sales Outstanding. This places BML in the lower half of its industry. The industry median Days Sales Outstanding is 67.59. BML's value of 71.72 is 6.1% above this benchmark. Historically, BML's own Days Sales Outstanding has ranged from 64.65 to 72.32 over the past decade. While the company's 10-year median is 65.60 vs. the industry median of 67.59, BML has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BML's current Days Sales Outstanding of 71.72 is 6.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BML and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BML's current Days Sales Outstanding is 71.72, which is near median its own 10-year median of 65.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current Days Sales Outstanding of 71.72. The stock's GF Value™ is $26.57, compared to a current price of $25.21 — trading 5.1% below its estimated fair value. The current Days Sales Outstanding is 71.72, which is near median its 10-year median of 65.60 and 6.1% above the Medical Diagnostics & Research industry median of 67.59. BML's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For BML (BMLKF), the current Days Sales Outstanding is 71.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 5.1% below its estimated GF Value™ of $26.57.
Key valuation signals for BMLKF:
Days Sales Outstanding: 71.72 (near median its 10-year median of 65.60)
GF Value™: $26.57 vs. price of $25.21 (5.1% below fair value)
Industry Position: 6.1% above the Medical Diagnostics & Research median (#102 of 201)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
69GF Score
Get the complete analysis for BMLKF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
